Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The Medicines Company - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'The Medicines Company - Product Pipeline Review - 2014', provides an overview of the The Medicines Company's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of The Medicines Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of The Medicines Company including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of The Medicines Company's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the The Medicines Company's pipeline products Reasons to buy - Evaluate The Medicines Company's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of The Medicines Company in its therapy areas of focus - Identify new drug targets and therapeutic classes in the The Medicines Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of The Medicines Company and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of The Medicines Company - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of The Medicines Company and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 The Medicines Company Snapshot 5 The Medicines Company Overview 5 Key Information 5 Key Facts 5 The Medicines Company - Research and Development Overview 6 Key Therapeutic Areas 6 The Medicines Company - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Combination Treatment Modalities 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 The Medicines Company - Pipeline Products Glance 14 The Medicines Company - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Filing rejected/Withdrawn Products/Combination Treatment Modalities 15 The Medicines Company - Clinical Stage Pipeline Products 16 Phase I Products/Combination Treatment Modalities 16 The Medicines Company - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 The Medicines Company - Drug Profiles 18 cangrelor 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 oritavancin disphosphate 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 (biapenem + RPX-7009) 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 (RPX-2014 + RPX-7009) 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 MDCO-216 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Rec Fibrinogen Injectable Hemostat 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 tigecycline 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 The Medicines Company - Pipeline Analysis 28 The Medicines Company - Pipeline Products by Target 28 The Medicines Company - Pipeline Products by Route of Administration 29 The Medicines Company - Pipeline Products by Molecule Type 30 The Medicines Company - Pipeline Products by Mechanism of Action 31 The Medicines Company - Recent Pipeline Updates 32 The Medicines Company - Dormant Projects 38 The Medicines Company - Discontinued Pipeline Products 39 Discontinued Pipeline Product Profiles 39 clopidogrel bisulfate 39 MDCO-2010 39 The Medicines Company - Company Statement 40 The Medicines Company - Locations And Subsidiaries 42 Head Office 42 Other Locations & Subsidiaries 42 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47
List of Tables The Medicines Company, Key Information 5 The Medicines Company, Key Facts 5 The Medicines Company - Pipeline by Indication, 2014 8 The Medicines Company - Pipeline by Stage of Development, 2014 9 The Medicines Company - Monotherapy Products in Pipeline, 2014 10 The Medicines Company - Combination Treatment Modalities in Pipeline, 2014 11 The Medicines Company - Partnered Products in Pipeline, 2014 12 The Medicines Company - Partnered Products/ Combination Treatment Modalities, 2014 13 The Medicines Company - Pre-Registration, 2014 14 The Medicines Company - Filing rejected/Withdrawn, 2014 15 The Medicines Company - Phase I, 2014 16 The Medicines Company - Preclinical, 2014 17 The Medicines Company - Pipeline by Target, 2014 28 The Medicines Company - Pipeline by Route of Administration, 2014 29 The Medicines Company - Pipeline by Molecule Type, 2014 30 The Medicines Company - Pipeline Products by Mechanism of Action, 2014 31 The Medicines Company - Recent Pipeline Updates, 2014 32 The Medicines Company - Dormant Developmental Projects,2014 38 The Medicines Company - Discontinued Pipeline Products, 2014 39 The Medicines Company, Other Locations 42 The Medicines Company, Subsidiaries 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.